Trials / Unknown
UnknownNCT05664152
An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
An Open-label, Bridging Study to Assess the Safety and Immunogenicity of BARYCELA Inj. (Live Attenuated Varicella Vaccine for Injection) in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- GC Biopharma Corp · Industry
- Sex
- All
- Age
- 12 Months – 12 Years
- Healthy volunteers
- Accepted
Summary
The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: * Safety of BARYCELA inj. (Live attenuated varicella vaccine for injection) * Immunogenicity of BARYCELA inj. (Live attenuated varicella vaccine for injection) Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MG1111 | BARYCELA inj. |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2023-04-01
- Completion
- 2023-06-01
- First posted
- 2022-12-23
- Last updated
- 2022-12-23
Source: ClinicalTrials.gov record NCT05664152. Inclusion in this directory is not an endorsement.